Complement 3 and factor H in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy

American Journal of Pathology

Volumn 178, Issue 4, 2011, Pages 1509-1516

  Wang, Yu ^a,b   Hancock, Aneeka M ^a   Bradner, Joshua ^a   Chung, Kathryn A ^c   Quinn, Joseph F ^c   Peskind, Elaine R ^a,d   Galasko, Douglas ^e   Jankovic, Joseph ^f   Zabetian, Cyrus P ^a,d   Kim, Hojoong M ^a,d   Leverenz, James B ^a,d   Montine, Thomas J ^a   Ginghina, Carmen ^a   Edwards, Karen L ^g   Snapinn, Katherine W ^g   Goldstein, David S ^h   Shi, Min ^a   Zhang, Jing ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; DEMENTIA; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RATING SCALE; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; TREATMENT INDICATION;

EID: 79953667345     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.01.006     Document Type: Article

References (37)

1. Morgan BP, Gasque P: Expression of complement in the brain: role in health and disease. Immunol Today 1996, 17:461-466 (Pubitemid 26323314)
2. Rus H, Cudrici C, David S, Niculescu F: The complement system in central nervous system diseases. Autoimmunity 2006, 39:395-402 (Pubitemid 44269617)
3. Morgan BP, Gasque P, Singhrao S, Piddlesden SJ: The role of complement in disorders of the nervous system. Immunopharmacology 1997, 38:43-50 (Pubitemid 28049962)
4. Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M: Expression of a complete and functional complement system by human neuronal cells in vitro. Int Immunol 2000, 12:1015-1023 (Pubitemid 30599354)
5. Ingram G, Hakobyan S, Hirst CL, Harris CL, Pickersgill TP, Cossburn MD, Loveless S, Robertson NP, Morgan BP: Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010, 133:1602-1611
6. Einstein LP, Hansen PJ, Ballow M, Davis AE III, Davis JS IV, Alper CA, Rosen FS, Colten HR: Biosynthesis of the third component of complement (C3) in vitro by monocytes from both normal and homozygous C3-deficient humans. J Clin Invest 1977, 60:963-969
7. Finehout EJ, Franck Z, Lee KH: Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 2005, 21:93-101 (Pubitemid 40875153)
8. Pasch MC, Van Den Bosch NH, Daha MR, Bos JD, Asghar SS: Synthesis of complement components C3 and factor B in human keratinocytes is differentially regulated by cytokines. J Invest Dermatol 2000, 114:78-82 (Pubitemid 30195976)
9. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K: Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008, 4:38-48
10. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746 (Pubitemid 47058377)
11. Alves G, Bronnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E: CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian Park West study. J Neurol Neurosurg Psychiatry 2010, 81:1080-1086
12. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Valldeoriola F, Munoz E, Ezquerra M, Rios J, Tolosa E: Cerebrospinal tau, phosphotau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009, 24:2203-2210
13. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J: CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010, 25:2682-2685
14. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C: CSF amyloid (beta) 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061
15. Fioravanzo L, Venturini M, Di Liddo R, Marchi F, Grandi C, Parnigotto PP, Folin M: Involvement of rat hippocampal astrocytes in betaamyloid- induced angiogenesis and neuroinflammation. Curr Alzheimer Res 2010, 7:591-601
16. Ager RR, Fonseca MI, Chu SH, Sanderson SD, Taylor SM, Woodruff TM, Tenner AJ: Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J Neurochem 2010, 113:389-401
17. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J: DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2009, 133:713-726
18. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, Kaufmann H, Klockgether T, Lang AE, Lantos PL, Litvan I, Mathias CJ, Oliver E, Robertson D, Schatz I, Wenning GK: Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999, 163:94-98 (Pubitemid 29155424)
19. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M: Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71:670-676
20. Fahn S, Elton R; UPDRS Committee: Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease, vol 2. Edited by S, Fahn CD, Marsden Calne Goldstein M. DB, Florham Park, NJ, Macmillan Healthcare Information, 1987, pp 153-163, 293-304
21. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B: Clinical diagnostic criteria for dementia associated with Parkinson's disease, Mov Disord 2007, 22:1689-1707; quiz 1837
22. Gibb WR, Lees AJ: The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988, 51:745-752
23. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414
24. Bonifati DM, Kishore U: Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 2007, 44:999-1010 (Pubitemid 44414994)
25. McGeer EG, Klegeris A, McGeer PL: Inflammation, the complement system and the diseases of aging. Neurobiol Aging 2005, 26(Suppl 1):94-97
26. Yasojima K, Schwab C, McGeer EG, McGeer PL: Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 1999, 154:927-936 (Pubitemid 29122612)
27. Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO: Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006, 21:958-963 (Pubitemid 44184596)
28. Van Laere K, Clerinx K, D'Hondt E, de Groot T, Vandenberghe W: Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 2010, 51:588-595
29. Guo J, Sun Z, Xiao S, Liu D, Jin G, Wang E, Zhou J, Zhou J: Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients. Cell Res 2009, 19:1401-1403
30. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH: Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934
31. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, Lindau M, Eriksdotter-Jonhagen M: Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 2008, 29:1466-1473
32. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR Jr: Serial MRI and CSF biomarkers in normal aging MCI, and AD. Neurology 2010, 75:143-151
33. Wahlund LO, Blennow K: Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003, 339:99-102
34. Bibl M, Esselmann H, Mollenhauer B, Weniger G, Welge V, Liess M, Lewczuk P, Otto M, Schulz JB, Trenkwalder C, Kornhuber J, Wiltfang J: Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J Neurochem 2007, 103:467-474 (Pubitemid 47498016)
35. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P: Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008, 64:850-855
36. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Kim HM, Leverenz JB, Montine TJ, Ginghina C, Kang UJ, Cain KC, Wang Y, Aasly J, Goldstein DS, Zhang J: Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2010, doi:10.1002/ana.22311
37. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R: Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res 2006, 31:1153-1162 (Pubitemid 44379676)